November 9, 2025
Here is a detailed explanation of Failure Mode and Effects Analysis (FMEA) and its critical relationship with pharmacovigilance
Here is a detailed explanation of Failure Mode and Effects Analysis (FMEA) and its critical relationship with pharmacovigilance
Underreporting is one of the most significant challenges in pharmacovigilance worldwide. Here is a detailed description covering what it is, its causes, how to fix it, and relevant examples.
The concept of the "7 Deadly Sins" is a powerful metaphor for persistent, systemic failures in patient safety. These are not just errors, but deep-seated cultural and procedural flaws that allow harm to spread.
This document is an official communication from the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). It summarizes the outcomes of their safety review meeting held from September 29 to October 2, 2025.
Medication safety is a critical discipline within healthcare dedicated to preventing errors and mitigating harm associated with the use of medicines throughout the entire medication use process. It represents a continuous, proactive effort that intersects strongly with pharmacovigilance. This article provides a detailed exploration of its definition, types of errors, practical applications, prevailing...
Explanation of Patient Engagement, with a specific focus on its role and growing importance in Pharmacovigilance (PV).
Eco-Pharmacovigilance (Eco-PV) is a critical and emerging field that extends the principles of pharmacovigilance from human safety to environmental safety. In simple terms, while traditional PV asks, "Is this drug safe for the patient?", Eco-PV asks, "Is this drug safe for the environment?"
Advancing Medication Safety Through Knowledge and Vigilance
